Today, Amgen shared its fourth quarter and full year 2025 earnings report. Amgen’s employees are united by our mission to serve patients. We harness the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller, and longer.
"Amgen delivered strong performance in 2025, with double-digit growth in revenues and earnings per share. We enter 2026 with momentum across a broad portfolio of medicines and a clear path towards advancing innovative therapies to deliver sustained long-term growth," said Robert A. Bradway, chairman and chief executive officer.
The infographic below provides more highlights about the company’s 2025 Q4/FY results.
Additional details can be found in the earnings press release. Please see forward-looking statements.
A webcast of the earnings call can be found on Amgen’s Investors page.
